BACKGROUND AND PURPOSE: Boosting the dose to the largest (dominant) lesion in radiotherapy of prostate cancer may improve treatment outcome.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The success of this approach relies on the detection and delineation of tumors. The agreement among teams of radiation oncologists and radiologists delineating lesions on multiparametric magnetic resonance imaging (mp-MRI) was assessed by measuring the distances between observer contours. The accuracy of detection and delineation was determined using whole-mount histopathology specimens as reference.
MATERIAL AND METHODS: Six observer teams delineated tumors on mp-MRI of 20 prostate cancer patients who underwent a prostatectomy. To assess the inter-observer agreement, the inter-observer standard deviation (SD) of the contours was calculated for tumor sites which were identified by all teams.
RESULTS: Eighteen of 89 lesions were identified by all teams, all were dominant lesions. The median histological volume of these was 2.4cm3. The median inter-observer SD of the delineations was 0.23cm. Sixty-six of 69 satellites were missed by all teams.
CONCLUSION: Since all teams identify most dominant lesions, dose escalation to the dominant lesion is feasible. Sufficient dose to the whole prostate may need to be maintained to prevent under treatment of smaller lesions and undetected parts of larger lesions.
Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, Kerkmeijer LG, Pameijer FA, Veldhuis WB, van der Voort van Zyp JR, Pos FJ, Heijmink SW, Kalisvaart R, Teertstra HJ, Dinh CV, Ghobadi G, van der Heide UA. Are you the author?
Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Radiation Oncology, University Hospitals Leuven, Department of Oncology, KU Leuven, Belgium; Pathology, University Hospitals Leuven, Department of Imaging & Pathology, KU Leuven, Belgium; Radiology, University Hospitals Leuven, Department of Imaging & Pathology, KU Leuven, Belgium; Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands; Department of Radiology, University Medical Center Utrecht, The Netherlands; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Reference: Radiother Oncol. 2015 May;115(2):186-90.